Skip to main content

Table 1 The clinicopathological features among PDAC patients in relation to T2DM status

From: Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes

VariablesWith T2DMWithout T2DMP value
N202601 
Age (years)61.7 (8.7)58.2 (10.9)<  0.001
Sex (male, %)120 (59.4)367 (61.1)0.676
BMI (kg/m2)23.4 (3.2)23.1 (3.3)0.183
Smoker (n, %)61 (30.2)206 (34.3)0.287
Drinking (n, %)44 (21.8)113 (18.8)0.356
FPG (mmol/L)8.45 (6.70–11.10)5.40 (4.95–6.10)<  0.001
Albumin (g/L)40.4 (6.7)40.1 (6.4)0.599
WBC (×109/L)7.38 (3.19)6.72 (2.77)0.005
Hemoglobin (g/dl)129.0 (15.2)129.9 (17.7)0.512
Platelet count (×109/L)216.6 (87.2)223.6 (78.0)0.278
MPV (fL)9.9 (1.9)10.3 (2.0)0.011
CA19–9 (IU/mL)  0.577
 ≤ 3738 (18.8)124 (20.6) 
 >  37164 (81.2)477 (79.4) 
Tumor location  0.240
 Head135 (66.8)374 (62.2) 
 Body, tail67 (33.2)227 (37.8) 
Tumor differentiation  0.092
 Well/moderate170 (84.2)533 (88.7) 
 Poor32 (15.8)68 (11.3) 
Tumor size (cm)  0.156
 ≤ 4158 (78.2)497 (82.7) 
 >  444 (21.8)104 (17.3) 
Regional lymph node metastasis  <  0.001
 N0124 (61.4)464 (77.2) 
 N169 (34.2)111 (18.5) 
 N29 (4.5)26 (4.3) 
Postoperative adjuvant chemotherapy  0.334
 Yes103 (51.0)330 (54.9) 
 No99 (49.0)271 (45.1) 
  1. T2DM type 2 diabetes mellitus; PDAC pancreatic ductal adenocarcinoma; BMI body mass index; FPG fasting plasma glucose; WBC white blood cells; MPV mean platelet volume